Focused On-demand Library for Intersectin-1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

SH3 domain-containing protein 1A; SH3P17

Alternative UPACC:

Q15811; A7Y322; A8CTX8; A8CTY3; A8CTY7; A8D7D0; A8DCP3; B4DTM2; E7ERJ1; E9PE44; E9PG01; E9PHV2; O95216; Q0PW94; Q0PW95; Q0PW97; Q14BD3; Q1ED40; Q20BK3; Q9UET5; Q9UK60; Q9UNK1; Q9UNK2; Q9UQ92


Intersectin-1, known alternatively as SH3 domain-containing protein 1A or SH3P17, is a pivotal adapter protein linking endocytic membrane traffic to the actin assembly machinery. It functions as a guanine nucleotide exchange factor for CDC42, enhancing actin nucleation via WASL and the ARP2/3 complex. This protein is crucial in clathrin-coated vesicle assembly, EGFR endocytosis, and synaptic vesicle endocytosis in neurons.

Therapeutic significance:

Understanding the role of Intersectin-1 could open doors to potential therapeutic strategies by elucidating its involvement in cellular trafficking and signaling pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.